What's Happening?
New research published in Nature Metabolism has raised concerns about the use of glucosamine supplements among individuals with Alzheimer's disease. The study found that those with Alzheimer's who took glucosamine were 25% more likely to die within five
years compared to those who did not take the supplement. Additionally, individuals with mild cognitive impairment who used glucosamine were more likely to progress to full Alzheimer's. The research also indicated that glucosamine could exacerbate memory issues in mice with Alzheimer's-like symptoms. These findings challenge previous beliefs that glucosamine could be beneficial for cognitive health.
Why It's Important?
This study highlights potential risks associated with glucosamine, a supplement widely used by over 40 million Americans for joint pain relief. The findings suggest that glucosamine may have adverse effects on cognitive health, particularly in individuals with Alzheimer's or those at risk of developing the disease. This could lead to a reevaluation of glucosamine's safety profile and its use in older adults, especially those with cognitive impairments. The research underscores the need for healthcare providers to carefully consider the potential risks and benefits of glucosamine for patients with Alzheimer's.
What's Next?
In light of these findings, further research is needed to explore the mechanisms by which glucosamine may influence cognitive decline and mortality in Alzheimer's patients. Scientists are also investigating compounds that could block the sugar molecules associated with glucosamine to mitigate its negative effects. Healthcare professionals may need to reassess their recommendations for glucosamine use, particularly in patients with cognitive impairments. Additionally, public health guidelines may be updated to reflect these new insights, potentially impacting the supplement industry and consumer choices.
